The Price of Progress

Contributors to this special issue examine prescription drug spending in the United States, including policy options aimed at controlling spending and improving access for patients. The authors explore the sources of high prices for medications in the US, proposals to curb spending for and enhance access to pharmaceutical treatments, and the tradeoffs associated with such reforms. Topics covered in the issue include current prescription drug legislation in Congress, future reform directions, and lessons from other countries’ experiences.

Contributors: Samantha G. Auty, Jerry Avorn, Peter B. Bach, Beatrice Brown, Jeanai Celestin, Rohan Chalasani, Amitabh Chandra, Michael Chernew, Rena M. Conti, Robert Cook-Deegan, Nicholas Corwin, Jonathan Darrow, Scott W. Delaney, Sean Dickson, Julie M. Donohue, Stacie B. Dusetzina, Utibe Essien, A. Mark Fendrick, Richard Frank, Nico Gabriel, Kyle A. Gavulic, Rebekah E. Gee, Walid Gellad, Kevin N. Griffith, Jonathan Gruber, Inmaculada Hernandez, Shelly A. Jazowski, Geoffrey Joyce, Krysten Joyce, Katrina M. Kaiser, Pragya Kakani, Aaron Kesselheim, Sudarshan Krishnamurthy,  Aaron Mitchell, Mayookha Mitra-Majumdar, Terri V. Newman, Jonathan Oberlander, Steven D. Pearson, Catherine Pham, Marc Rodwin, Murray Ross, Rachel Sachs, Ameet Sarpatwari, Paul R. Shafer, Nicholas Smith, Katie J. Suda, Erin Trish, Joseph White